These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

188 related items for PubMed ID: 19938382

  • 21. Abbreviated New Drug Applications: Generic Drug User Fee Amendments Act Analysis of Application Quality Metrics.
    Woo J, Luan JJ, Li Z, Grosser S, Peters J, Chazin H.
    Ther Innov Regul Sci; 2019 Sep; 53(5):696-700. PubMed ID: 30360656
    [Abstract] [Full Text] [Related]

  • 22. Evolving brand-name and generic drug competition may warrant a revision of the Hatch-Waxman Act.
    Grabowski HG, Kyle M, Mortimer R, Long G, Kirson N.
    Health Aff (Millwood); 2011 Nov; 30(11):2157-66. PubMed ID: 22068409
    [Abstract] [Full Text] [Related]

  • 23. Recent trends in brand-name and generic drug competition.
    Grabowski H, Long G, Mortimer R.
    J Med Econ; 2014 Mar; 17(3):207-14. PubMed ID: 24320785
    [Abstract] [Full Text] [Related]

  • 24. A brief history of 180-day exclusivity under the Hatch-Waxman Amendments to the Federal Food, Drug, and Cosmetic Act.
    Lietzan EK.
    Food Drug Law J; 2004 Mar; 59(2):287-323. PubMed ID: 15298013
    [Abstract] [Full Text] [Related]

  • 25. FDA's role in making exclusivity determinations.
    Dickinson EH.
    Food Drug Law J; 1999 Mar; 54(2):195-203. PubMed ID: 11758573
    [No Abstract] [Full Text] [Related]

  • 26. New drug applications and abbreviated new drug applications; technical amendment. Final rule; technical amendment.
    Food and Drug Administration, HHS.
    Fed Regist; 2009 Mar 06; 74(43):9765-6. PubMed ID: 19418639
    [Abstract] [Full Text] [Related]

  • 27. The right to a jury trial in actions under the Waxman-Hatch Act.
    Coggio BD, Bresnick SA.
    Food Drug Law J; 1997 Mar 06; 52(3):259-76. PubMed ID: 10343025
    [No Abstract] [Full Text] [Related]

  • 28. The balance between innovation and competition: the Hatch-Waxman Act, the 2003 Amendments, and beyond.
    Kelly C.
    Food Drug Law J; 2011 Mar 06; 66(3):417-78, iii. PubMed ID: 24505856
    [Abstract] [Full Text] [Related]

  • 29. Hatch-Waxman Turns 30: Do We Need a Re-Designed Approach for the Modern Era?
    Kesselheim AS, Darrow JJ.
    Yale J Health Policy Law Ethics; 2015 Mar 06; 15(2):293-347. PubMed ID: 26333236
    [Abstract] [Full Text] [Related]

  • 30. Updated trends in US brand-name and generic drug competition.
    Grabowski H, Long G, Mortimer R, Boyo A.
    J Med Econ; 2016 Sep 06; 19(9):836-44. PubMed ID: 27064194
    [Abstract] [Full Text] [Related]

  • 31. On access and accountability--two Supreme Court rulings on generic drugs.
    Boumil MM, Curfman GD.
    N Engl J Med; 2013 Aug 22; 369(8):696-7. PubMed ID: 23923990
    [No Abstract] [Full Text] [Related]

  • 32. Striking the right balance between innovation and drug price competition: understanding the Hatch-Waxman Act--an introduction of speakers.
    Rea TS.
    Food Drug Law J; 1999 Aug 22; 54(2):223-5. PubMed ID: 11759713
    [No Abstract] [Full Text] [Related]

  • 33. How drug life-cycle management patent strategies may impact formulary management.
    Berger J, Dunn JD, Johnson MM, Karst KR, Shear WC.
    Am J Manag Care; 2016 Oct 22; 22(16 Suppl):S487-S495. PubMed ID: 28719222
    [Abstract] [Full Text] [Related]

  • 34. Drug marketing exclusivity under United States and European Union law.
    Junod V.
    Food Drug Law J; 2004 Oct 22; 59(4):479-518. PubMed ID: 15875347
    [No Abstract] [Full Text] [Related]

  • 35. Issues in the interpretation of 180-day exclusivity.
    Lietzan E, Korn DE.
    Food Drug Law J; 2007 Oct 22; 62(1):49-75. PubMed ID: 17444026
    [No Abstract] [Full Text] [Related]

  • 36. The right to a jury trial under the Waxman-Hatch Act--the question revisited and resolved.
    Coggio BD, DeMasi TE.
    Food Drug Law J; 2002 Oct 22; 57(1):155-60. PubMed ID: 12118478
    [No Abstract] [Full Text] [Related]

  • 37. Revitalizing the patent system to incentivize pharmaceutical innovation: the potential of claims with means-plus-function clauses.
    Tang WL.
    Duke Law J; 2013 Feb 22; 62(5):1069-108. PubMed ID: 25330553
    [Abstract] [Full Text] [Related]

  • 38. Unsettling drug patent settlements: a framework for presumptive illegality.
    Carrier MA.
    Mich Law Rev; 2009 Oct 22; 108(1):37-80. PubMed ID: 20535881
    [Abstract] [Full Text] [Related]

  • 39. The timing of 30-month stay expirations and generic entry: A cohort study of first generics, 2013-2020.
    Kannappan S, Darrow JJ, Kesselheim AS, Beall RF.
    Clin Transl Sci; 2021 Sep 22; 14(5):1917-1923. PubMed ID: 33982425
    [Abstract] [Full Text] [Related]

  • 40. The Hatch-Waxman Act during patent prosecution and beyond.
    Mahn TG.
    Food Drug Law J; 1999 Sep 22; 54(2):233-6. PubMed ID: 11758578
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 10.